Dyadic International (NASDAQ:DYAI) Shares Cross Below 50-Day Moving Average – Here’s Why

Dyadic International Inc. (NASDAQ:DYAI) shares passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.79 and traded as low as $0.6870. Dyadic International shares last traded at $0.7106, with a volume of 79,647 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research note on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Dyadic International has an average rating of “Hold” and an average target price of $3.00.

Dyadic International Price Performance

The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. The company has a 50-day simple moving average of $0.79 and a two-hundred day simple moving average of $0.85. The stock has a market capitalization of $25.89 million, a price-to-earnings ratio of -3.09 and a beta of 1.17.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The company had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. On average, equities research analysts predict that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On Dyadic International

Several large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its position in Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the period. Marathon Capital Management acquired a new stake in Dyadic International in the third quarter worth $41,000. Geode Capital Management LLC increased its position in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the period. Truist Financial Corp increased its position in Dyadic International by 30.5% in the third quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after buying an additional 76,200 shares during the period. Finally, Landscape Capital Management L.L.C. acquired a new stake in Dyadic International in the third quarter worth $190,000. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.